Caribou Biosciences
Open
$1.61
Prev. Close
$1.61
High
$1.61
Low
$1.59
Market Snapshot
$154.14M
-1.2
-1.62
$9.92M
97
Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. The company is headquartered in Berkeley, California and currently employs 97 full-time employees. The company went IPO on 2021-07-23. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform to offer broad access and rapid availability of treatments for patients with hematologic malignancies and autoimmune diseases. Its genome-editing platform, including its novel chRDNA technology, enables more precise genome editing of allogeneic cell therapies. The company is advancing its pipeline of allogeneic CAR-T cell therapies with clinical development programs targeting the treatment of hematologic malignancies and autoimmune diseases.
Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. The company is headquartered in Berkeley, California and currently employs 97 full-time employees. The company went IPO on 2021-07-23. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform to offer broad access and rapid availability of treatments for patients with hematologic malignancies and autoimmune diseases. Its genome-editing platform, including its novel chRDNA technology, enables more precise genome editing of allogeneic cell therapies. The company is advancing its pipeline of allogeneic CAR-T cell therapies with clinical development programs targeting the treatment of hematologic malignancies and autoimmune diseases.
Recently from Cashu
Caribou Biosciences Hit with Class Action Lawsuit Over Misleading Investor Statements
Caribou Biosciences Faces Class Action Lawsuit Over Allegations of Misleading Statements Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, finds itself embroiled in a class action…
Caribou Biosciences Faces Class-Action Lawsuit Over Alleged Misrepresentation of CB-010 Therapy Efficacy
Caribou Biosciences Faces Legal Scrutiny Over Alleged Misrepresentation of Therapy Efficacy Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, finds itself at the center of a class…
PFM Health Sciences Boosts Investment in Caribou Biosciences, Highlighting Confidence in CRISPR Technology
PFM Health Sciences Increases Stake in Caribou Biosciences, Signaling Confidence in CRISPR Innovations PFM Health Sciences, LP has recently strengthened its investment in Caribou Biosciences Inc., a c…
PFM Boosts Confidence in Caribou Biosciences' CRISPR Technology with Increased Investment
Investment Signals Confidence in CRISPR Technology at Caribou Biosciences PFM Health Sciences, LP recently enhances its commitment to Caribou Biosciences Inc., a clinical-stage biopharmaceutical compa…